News articles about Ra Pharmaceuticals (NASDAQ:RARX) have trended somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ra Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.8601149092719 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

RARX has been the topic of several analyst reports. Zacks Investment Research lowered shares of Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Jefferies Group set a $25.00 price target on shares of Ra Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 25th. Royal Bank of Canada initiated coverage on shares of Ra Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $21.00 price target on the stock. Credit Suisse Group raised their price target on shares of Ra Pharmaceuticals from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday, November 10th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $34.00 price target (up previously from $31.00) on shares of Ra Pharmaceuticals in a research note on Monday, December 4th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Ra Pharmaceuticals currently has an average rating of “Buy” and an average price target of $23.20.

Shares of Ra Pharmaceuticals (RARX) traded up $0.06 during trading hours on Thursday, hitting $8.06. 341,100 shares of the company’s stock traded hands, compared to its average volume of 137,422. Ra Pharmaceuticals has a 12 month low of $7.15 and a 12 month high of $27.84.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.06). equities research analysts forecast that Ra Pharmaceuticals will post -2.46 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Ra Pharmaceuticals (RARX) Receiving Somewhat Positive Press Coverage, Analysis Shows” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Insider Buying and Selling by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with's FREE daily email newsletter.